EVOMMUNE INC
EVMNNYSETrading Snapshot
- Day Range
- —
- 52-Week Range
- $4.94 – $33.20
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 36.3M
- Next Earnings
- 2026-12-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 11.7x
- EPS (TTM)
- $-3.83
- Dividend Yield
- —
EVOMMUNE INC
EVMNFinancial history unavailable.
StockOtter · stockotter.spaceAbout EVOMMUNE INC
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
News unavailable.